Movement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty

Market Focus06-01

On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector correction and emerging concerns over regulatory approval uncertainty surrounding its recently announced Pfizer partnership.

On May 29, Innovent Biologics announced a landmark global strategic licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, with a total deal value of up to USD 10.5 billion including a USD 650 million upfront payment and up to USD 9.85 billion in milestone payments. The stock surged over 11% on the announcement day. However, given that the 12 programs are still at early stages and require extensive regulatory approvals across multiple jurisdictions, market participants have begun pricing in execution risk.

The broader biotech sector weighed heavily on sentiment, with BEIGENE down 3.28%, Remegen down 5.08%, and SKB Bio down 3.64%. This systemic selling pressure compounded the post-rally profit-taking in Innovent following its sharp gain last week.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168228623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168228623","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty","media":"Market Focus","content":"<p><p>On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector correction and emerging concerns over regulatory approval uncertainty surrounding its recently announced Pfizer partnership.</p><p>On May 29, Innovent Biologics announced a landmark global strategic licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, with a total deal value of up to USD 10.5 billion including a USD 650 million upfront payment and up to USD 9.85 billion in milestone payments. The stock surged over 11% on the announcement day. However, given that the 12 programs are still at early stages and require extensive regulatory approvals across multiple jurisdictions, market participants have begun pricing in execution risk.</p><p>The broader biotech sector weighed heavily on sentiment, with BEIGENE down 3.28%, Remegen down 5.08%, and SKB Bio down 3.64%. This systemic selling pressure compounded the post-rally profit-taking in Innovent following its sharp gain last week.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector correction and emerging concerns over regulatory approval uncertainty surrounding its recently announced Pfizer partnership.</p><p>On May 29, Innovent Biologics announced a landmark global strategic licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, with a total deal value of up to USD 10.5 billion including a USD 650 million upfront payment and up to USD 9.85 billion in milestone payments. The stock surged over 11% on the announcement day. However, given that the 12 programs are still at early stages and require extensive regulatory approvals across multiple jurisdictions, market participants have begun pricing in execution risk.</p><p>The broader biotech sector weighed heavily on sentiment, with BEIGENE down 3.28%, Remegen down 5.08%, and SKB Bio down 3.64%. This systemic selling pressure compounded the post-rally profit-taking in Innovent following its sharp gain last week.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1168228623","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168228623","pubTimestamp":1780283920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提示|信达生物常规交易跌3.12%生物科技板块回调加剧辉瑞交易监管不确定性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector correction and emerging concerns over regulatory approval uncertainty surrounding its recently announced Pfizer partnership.On May 29, Innovent Biologics announced a landmark global strategic licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, with a total deal value of up to USD 10.5 billion including a USD 650 million upfront payment and up to USD 9.85 billion in milestone payments. The stock surged over 11% on the announcement day. However, given that the 12 programs are still at early stages and require extensive regulatory approvals across multiple jurisdictions, market participants have begun pricing in execution risk.The broader biotech sector weighed heavily on sentiment, with BEIGENE down 3.28%, Remegen down 5.08%, and SKB Bio down 3.64%. This systemic selling pressure compounded the post-rally profit-taking in Innovent following its sharp gain last week.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168228623","isCrawlerRequest":true}